Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 | 2024 | 803 | 5.040 |
Why?
|
| Cerebellar Neoplasms | 8 | 2024 | 283 | 3.110 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2024 | 178 | 3.010 |
Why?
|
| Methotrexate | 7 | 2024 | 341 | 2.900 |
Why?
|
| Medulloblastoma | 7 | 2024 | 338 | 2.870 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2024 | 48 | 2.610 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2024 | 193 | 2.190 |
Why?
|
| Craniospinal Irradiation | 3 | 2023 | 58 | 1.730 |
Why?
|
| Overweight | 5 | 2022 | 343 | 1.610 |
Why?
|
| Firefighters | 4 | 2016 | 32 | 1.530 |
Why?
|
| Cancer Survivors | 7 | 2022 | 187 | 1.280 |
Why?
|
| DNA Methylation | 6 | 2020 | 991 | 1.100 |
Why?
|
| Child | 37 | 2024 | 24079 | 1.060 |
Why?
|
| Cisplatin | 4 | 2024 | 255 | 1.010 |
Why?
|
| Obesity | 6 | 2020 | 2085 | 1.000 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2022 | 52 | 1.000 |
Why?
|
| Pharmacogenomic Variants | 1 | 2024 | 35 | 0.960 |
Why?
|
| Proton Therapy | 2 | 2024 | 120 | 0.910 |
Why?
|
| Metabolomics | 3 | 2021 | 395 | 0.890 |
Why?
|
| Neoplasms | 4 | 2022 | 2753 | 0.870 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 122 | 0.860 |
Why?
|
| Weight Loss | 3 | 2016 | 443 | 0.830 |
Why?
|
| Child, Preschool | 21 | 2024 | 13790 | 0.810 |
Why?
|
| Survivors | 4 | 2022 | 345 | 0.800 |
Why?
|
| Metabolome | 2 | 2021 | 292 | 0.790 |
Why?
|
| Genome-Wide Association Study | 8 | 2023 | 1630 | 0.790 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 29 | 0.760 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 1222 | 0.750 |
Why?
|
| Down Syndrome | 2 | 2022 | 194 | 0.720 |
Why?
|
| Hypothyroidism | 1 | 2021 | 89 | 0.720 |
Why?
|
| Male | 36 | 2024 | 59559 | 0.710 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 222 | 0.690 |
Why?
|
| Dried Blood Spot Testing | 1 | 2020 | 22 | 0.690 |
Why?
|
| Bone Marrow | 1 | 2021 | 318 | 0.680 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 173 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2020 | 2573 | 0.640 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 162 | 0.640 |
Why?
|
| Prognosis | 9 | 2024 | 4490 | 0.630 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 228 | 0.630 |
Why?
|
| Humans | 49 | 2024 | 122349 | 0.620 |
Why?
|
| Neonatal Screening | 1 | 2020 | 187 | 0.600 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 152 | 0.580 |
Why?
|
| Female | 31 | 2024 | 64923 | 0.570 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 59 | 0.570 |
Why?
|
| Adolescent | 18 | 2024 | 18959 | 0.570 |
Why?
|
| Weight Gain | 2 | 2019 | 382 | 0.570 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.540 |
Why?
|
| Cardiomyopathies | 1 | 2021 | 479 | 0.530 |
Why?
|
| Ear Diseases | 1 | 2015 | 18 | 0.510 |
Why?
|
| Biomarkers | 2 | 2021 | 2945 | 0.500 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 141 | 0.490 |
Why?
|
| DNA | 1 | 2020 | 1606 | 0.470 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2023 | 3050 | 0.450 |
Why?
|
| Mucositis | 2 | 2024 | 18 | 0.440 |
Why?
|
| Genome, Human | 1 | 2020 | 1251 | 0.430 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 438 | 0.430 |
Why?
|
| Health Status | 1 | 2014 | 370 | 0.400 |
Why?
|
| Fatigue | 3 | 2022 | 218 | 0.380 |
Why?
|
| Genetic Variation | 3 | 2019 | 1462 | 0.370 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5013 | 0.350 |
Why?
|
| Body Mass Index | 5 | 2020 | 1463 | 0.350 |
Why?
|
| Hearing Loss | 2 | 2024 | 132 | 0.350 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 921 | 0.330 |
Why?
|
| Retrospective Studies | 8 | 2024 | 15858 | 0.330 |
Why?
|
| Infant | 9 | 2024 | 12307 | 0.320 |
Why?
|
| Hypospadias | 2 | 2020 | 81 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 162 | 0.310 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 69 | 0.310 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 1677 | 0.300 |
Why?
|
| Young Adult | 8 | 2024 | 8775 | 0.300 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 1298 | 0.290 |
Why?
|
| Incidence | 4 | 2022 | 3018 | 0.280 |
Why?
|
| Hodgkin Disease | 2 | 2020 | 293 | 0.260 |
Why?
|
| Laxatives | 1 | 2024 | 9 | 0.240 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2024 | 29 | 0.240 |
Why?
|
| Creatinine | 2 | 2023 | 379 | 0.230 |
Why?
|
| Cochlea | 1 | 2024 | 87 | 0.230 |
Why?
|
| Risk Factors | 9 | 2022 | 9903 | 0.230 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 180 | 0.220 |
Why?
|
| Adult | 13 | 2024 | 28764 | 0.220 |
Why?
|
| Genotype | 3 | 2020 | 2525 | 0.220 |
Why?
|
| Constipation | 1 | 2024 | 113 | 0.220 |
Why?
|
| Counselors | 1 | 2023 | 22 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 37 | 0.210 |
Why?
|
| Intelligence | 1 | 2023 | 98 | 0.210 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.210 |
Why?
|
| Cultural Competency | 1 | 2023 | 52 | 0.210 |
Why?
|
| Asparaginase | 1 | 2022 | 41 | 0.210 |
Why?
|
| Censuses | 1 | 2022 | 11 | 0.200 |
Why?
|
| Genetic Counseling | 1 | 2023 | 221 | 0.190 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 99 | 0.190 |
Why?
|
| Protons | 1 | 2021 | 91 | 0.190 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 185 | 0.190 |
Why?
|
| Growth Hormone | 1 | 2021 | 151 | 0.190 |
Why?
|
| Executive Function | 1 | 2021 | 101 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2020 | 4643 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 130 | 0.180 |
Why?
|
| Case-Control Studies | 5 | 2023 | 3229 | 0.180 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.180 |
Why?
|
| Rhabdomyosarcoma | 1 | 2023 | 194 | 0.180 |
Why?
|
| Forecasting | 1 | 2022 | 355 | 0.180 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 665 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2022 | 178 | 0.170 |
Why?
|
| Biliary Atresia | 1 | 2023 | 201 | 0.170 |
Why?
|
| Ikaros Transcription Factor | 1 | 2019 | 29 | 0.170 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 39 | 0.170 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 214 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 161 | 0.170 |
Why?
|
| Diacylglycerol Kinase | 1 | 2019 | 15 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2020 | 137 | 0.160 |
Why?
|
| Age Factors | 4 | 2024 | 2777 | 0.160 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 67 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 101 | 0.160 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 122 | 0.160 |
Why?
|
| Sleep | 1 | 2021 | 344 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 184 | 0.160 |
Why?
|
| Residence Characteristics | 1 | 2020 | 265 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2022 | 1363 | 0.160 |
Why?
|
| Leukocyte Count | 1 | 2019 | 246 | 0.150 |
Why?
|
| SEER Program | 1 | 2019 | 193 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 180 | 0.150 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 138 | 0.150 |
Why?
|
| Gene Frequency | 1 | 2019 | 703 | 0.150 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 354 | 0.150 |
Why?
|
| Adiposity | 2 | 2020 | 181 | 0.140 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 872 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 403 | 0.140 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 1823 | 0.140 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 91 | 0.140 |
Why?
|
| Middle Aged | 4 | 2019 | 25655 | 0.140 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2016 | 21 | 0.140 |
Why?
|
| Computational Biology | 1 | 2021 | 789 | 0.140 |
Why?
|
| Recurrence | 1 | 2020 | 1413 | 0.140 |
Why?
|
| Neutrophils | 1 | 2019 | 371 | 0.140 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 459 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 217 | 0.130 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 303 | 0.130 |
Why?
|
| Registries | 1 | 2022 | 1368 | 0.130 |
Why?
|
| Directive Counseling | 1 | 2015 | 25 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 367 | 0.120 |
Why?
|
| Prevalence | 2 | 2022 | 2373 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 845 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2014 | 84 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1192 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1674 | 0.110 |
Why?
|
| Self Report | 1 | 2016 | 498 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2020 | 5974 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 1424 | 0.100 |
Why?
|
| Counseling | 1 | 2014 | 218 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 738 | 0.100 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 3302 | 0.100 |
Why?
|
| Health Personnel | 1 | 2016 | 500 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2019 | 2029 | 0.090 |
Why?
|
| Alleles | 1 | 2015 | 1579 | 0.090 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 423 | 0.090 |
Why?
|
| Pediatrics | 1 | 2019 | 1140 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8097 | 0.080 |
Why?
|
| Transcription Factors | 1 | 2019 | 2579 | 0.080 |
Why?
|
| United States | 4 | 2018 | 10494 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2997 | 0.080 |
Why?
|
| CpG Islands | 2 | 2020 | 321 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 99 | 0.060 |
Why?
|
| Mediator Complex | 1 | 2023 | 52 | 0.050 |
Why?
|
| Hyperbilirubinemia | 1 | 2022 | 43 | 0.050 |
Why?
|
| Germ Cells | 1 | 2023 | 193 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 238 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 223 | 0.050 |
Why?
|
| Homozygote | 1 | 2023 | 521 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 217 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 346 | 0.040 |
Why?
|
| Carbohydrate Metabolism | 1 | 2019 | 54 | 0.040 |
Why?
|
| Arkansas | 1 | 2019 | 56 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 450 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 1090 | 0.040 |
Why?
|
| Exome | 1 | 2023 | 1012 | 0.040 |
Why?
|
| Texas | 2 | 2016 | 3530 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 525 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 93 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 553 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2018 | 3307 | 0.040 |
Why?
|
| Amino Acids | 1 | 2019 | 660 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 179 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1249 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1016 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 1234 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2023 | 1521 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 665 | 0.030 |
Why?
|
| Tobacco Use | 1 | 2014 | 24 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2014 | 65 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 1215 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 1354 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3291 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 336 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1250 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 2535 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1772 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1490 | 0.020 |
Why?
|